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with minor effect in *2/*2 carriers. After 900mg LD, the effect of the
CYP2C19*2 variant on platelet inhibition was fully compensated in wt/*2 car-
riers but not in *2/*2 carriers (–83.6±25.8% in wt/wt vs. –77.2±26.9% in wt/
*2 vs. –29.5±26.8% in *2/*2; overall p-value=0.0003, p=0.20 for wt/wt versus
wt/*2, p<0.001 for wt/*2 versus *2/*2). A similar pattern was observed for the
active metabolite AUC0-6 and there was a significant correlation between PK
and PD responses irrespective of the LD. 
Conclusion: Carriers of CYP2C19*2 display significant lower responses to
clopidogrel with a gene dose-effect. Clopidogrel resistance can be overcome by
increasing the dose in heterozygous carriers but not in homozygous carriers. 
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Purpose: There is no consensus on how to manage the switch from clopido-
grel to prasugrel immediately after a clopidogrel loading dose (LD). The aim of
this study was to evaluate the pharmacodynamic response of switching patients in
this situation and comparing two prasugrel reloading doses (RD) by using three
laboratory tests. Methods: Patients hospitalized for acute coronary syndrome
(ACS) who received a 300 mg LD of clopidogrel before admission were referred
for inclusion. Their platelet response to the P2Y12 inhibitor was tested with vaso-
dilator-stimulated phosphoprotein phosphorylation (VASP), Verify Now assay
and light transmission aggregometry (LTA) on admission (T1). Then, patients
were immediately randomized for 2 RD of prasugrel (10 mg or 30 mg) and
platelet response was tested again by the same methods (T2). Results: 20 patients
were included in each group. All T1 and T2 analyses were performed during the
first 24 hours after hospitalization. Compared with a 300 mg LD of clopidogrel,
the proportion of patients with platelet hyporesponsiveness for VASP to the
P2Y12 inhibitor was lower after the prasugrel RD: 8 vs 1 (p<0.001) in the 10 mg
prasugrel group and 12 vs none (p<0.001) in the 30 mg prasugrel group. Late ade-
nosine diphosphate-induced platelet aggregation (LPA), by LTA was lower after
a 30 mg prasugrel RD compared with a 10 mg RD (mean LPA 8 +/–9 vs 14 +/–
12; p<0.001). Similar results were found using VerifyNow P2Y12 (mean PRU 38
+/–60 vs 87 +/–71; p < 0.001) and VASP assays (mean PRI 17 +/– 12 vs 33 +/–
15; p<0.001). No bleeding events were reported during the hospital stay. 
Conclusions: For patients receiving 300 mg clopidogrel therapy after an
ACS, a 30 mg RD of prasugrel compared to a 10 mg RD is associated with
further reduction in platelet function and markedly decreases the proportion of
P2Y12 inhibitors low responders.
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Background: Despite encouraging short and mid-term results with drug-
eluting stents (DES) in diabetic (DM) patients (pts) with coronary artery dis-
ease, the long-term efficacy is controversial. We assessed the influence of
long-term dual antiplatelet treatment (DAPLT) with aspirin and clopidogrel on
clinical outcome of DM pts treated with DES. 
Methods: The study included 610 consecutive DM pts (male 80%, mean
age 65±9 years) that had been treated with DES. Five years clinical follow-up
(FU) obtained in 584/610 (96%) of them. At the end of follow-up, 341 (58%)
pts were on DAPLT and 243 (42%) on single antiplatelet treatment (SAPLT).
The primary end-point was the combination of death (D), non-fatal myocardial
infarction (MI) and cerebrovascular accident (CVA), and was considered as
hard end-point (HEP). Stent thrombosis (ST) occurring -12 months after DES
implantation was considered as early (EST), and for >12 months, as late
(LST). The ARC definition for ST was used. 
Results: There was no difference in gender, age, risk factors profile,
unstable coronary artery disease, insulin treatment, extent of coronary artery
disease, and systolic left ventricular function between the two groups. At
12 months post PCI 546 (92%) pts were on DAPLT; the incidence of EST
(definite or probable) was 0.8%. The incidence of LST (definite or probable)
was 0.7%. There was no difference in the incidence of ST in pts treated with
DAPLT vs. SAPLT (1.4% vs. 1.6%, p: ns). At FU, HEP was observed in 18%
vs. 13%, in pts on DAPLT vs. SAPLT (p: ns). 
Conclusion: Long-term DAPLT in DM pts treated with DES implantation
is not associated with better clinical outcome or lower risk of definite or prob-
able ST. 
037
Incidence and predictors of coronary stent thrombosis: evidence from
an international collaborative meta-analysis including 32 studies,
222,752 patients, and 4490 thromboses
Gilles Lemesle [Orateur] (1), Fabrizio D’Ascenzo (2), Mario Bollati (2),
Bo Lagerqvist (3), Ron Waksman (4), Jose De La Torre Hernandez (5),
Gregg Stone (6), Antonio Colombo (7), Piergiovanni Buonamici (8), Giu-
seppe Biondi-Zoccai (9)
(1) CHRU Cardiologie, Centre Hémodynamique, Lille, France – (2) University
of Turin, Division of Cardiology, Turin, Italia – (3) Uppsala Clinical Research
Centre, Uppsala University, Division of Cardiology, Uppsala, Sweden – (4)
Washington Hospital Center, Washington DC, United-States – (5) Hospital
Marques de Valdecilla, Division of Cardiology, Santander, Spain – (6) Colum-
bia University Medical Center and the Cardiovascular Research Foundation,
New-York, Ny, United-States – (7) Centro Cuore Columbus, Milan, Italia – (8)
Careggi Hospital, Department of Cardiology, Florence, Italia – (9) University
of Modena and Reggio Emilia, Division of Cardiology, Modena, Italia
Background: Stent thrombosis remains among the most feared complica-
tions of percutaneous coronary intervention (PCI) with stenting. However,
data on its incidence and predictors are sparse and conflicting. 
Objective: We aimed to perform a collaborative systematic review on inci-
dence and predictors of stent thrombosis. PubMed was systematically searched for
eligible studies from the drug-eluting stent (DES) era (1/2002-12/2010).
Methods: Studies were selected if including 2,000 patients undergoing
stenting or reporting on 25 thromboses. Study features, patient characteris-
tics, incidence and predictors of stent thrombosis were abstracted and pooled,
when appropriate, with random-effect methods (point estimate [95% confi-
dence intervals]).
Results: A total of 32 studies were identified (222,752 patients, 4,490 throm-
boses), with DES used in 89%. After a median of 22 months, definite, probable, or
possible stent thrombosis had occurred in 2.3% (2.0%; 2.6%), with acute in 0.3%
(0.2%; 0.5%), subacute in 1.1% (0.9%; 1.3%), late in 0.5% (0.4%; 0.6%), and very
late in 0.6% (0.4%; 0.7%). Similar figures were computed for studies reporting
only on DES, except for lower rates of acute ST (0.2% [0.1%; 0.2%]). From a total
of 47 candidate variables, the most reliable predictors of definite/probable stentPlatelet inhibition tested by Verify Now and VASP
